Advitech announced its first significant sales of psoriasis
supplement Dermylex have propped-up financial results for its third
quarter ended September 30, 2006.
Advitech's global roll out plan for its psoriasis nutraceutical
Dermylex is coming together, with definitive agreements in Canada
and France, interim financing, and new appointments as it moves
into the implementation phase.
Advitech is embroiled in discussions with potential partners to
bring its XP-828L product to market, targeting sufferers of mild to
moderate psoriasis and other inflammatory diseases.
Canada's Advitech is continuing with the clinical trial program for
XP-828L sweet whey protein extract to give the product weight with
dermatologists and help it achieve its market potential - an effort
which led the biotech...